Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Antithrombotic treatment in acute coronary syndrome and atrial fibrillation].

Herz·2019

Same author

The German CPU registry: Comparison of smokers and nonsmokers.

Herz·2018

Same author

[Hemorrhage under direct oral anticoagulants : Occurrence and treatment in intensive care patients].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2018

Same author

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?

Clinical research in cardiology : official journal of the German Cardiac Society·2018

Same author

[NOAC: Real-life data and the role of antidotes for the treatment of bleeding].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2017

Same author

[Bleeding in patients receiving dual antiplatelet therapy after acute coronary syndrome - significance, prevention and interdisciplinary management].

Deutsche medizinische Wochenschrift (1946)·2016

Same journal

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026

Same journal

Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

Hamostaseologie·2026

Same journal

Hamostaseologie·2026

Same journal

Hamostaseologie·2026

Same journal

Hamostaseologie·2026

Same journal

Hamostaseologie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 20, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

[Prasugrel].

¹Klinik fur Kardiologie, Angiologie & konservative Intensivmedizin, Vivantes Klinikum Neukolln, Berlin. harald.darius@vivantes.de

Hamostaseologie

|July 17, 2012

Summary

This summary is machine-generated.

Prasugrel offers faster and more consistent platelet inhibition than clopidogrel for acute coronary syndrome patients, reducing events and stent thrombosis. Specific patient groups, like those with diabetes, show greater benefit, though bleeding risks exist in the elderly and underweight.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Experiment Videos

Last Updated: May 20, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Area of Science:

Cardiology
Pharmacology
Thrombosis Research

Context:

Atherosclerotic vascular disease necessitates effective antithrombotic therapies.
Dual antiplatelet therapy with aspirin and clopidogrel is standard but has limitations.
Newer agents like prasugrel aim to improve upon existing treatments.

Purpose:

To evaluate the efficacy and safety of prasugrel compared to clopidogrel.
To assess prasugrel's impact on platelet inhibition and clinical outcomes.
To identify patient subgroups benefiting most from prasugrel.

Summary:

Prasugrel demonstrates superior platelet inhibition with faster onset and less variability than clopidogrel.
Clinical trials prove prasugrel's therapeutic advantage in reducing coronary events and stent thrombosis in acute coronary syndrome patients.
Patients with diabetes mellitus and ST-elevation myocardial infarction show significant benefits, while elderly and low-weight individuals require dose adjustment due to bleeding risk.

Impact:

Prasugrel represents a significant advancement in antiplatelet therapy for managing atherosclerotic vascular disease.
Improved outcomes in high-risk patient populations, including those with diabetes, are a key clinical implication.
Guidelines may evolve to incorporate prasugrel more broadly, with specific dosing recommendations for vulnerable groups.